These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 10706022

  • 1. Ocular motor abnormalities in Gaucher disease.
    Harris CM, Taylor DS, Vellodi A.
    Neuropediatrics; 1999 Dec; 30(6):289-93. PubMed ID: 10706022
    [Abstract] [Full Text] [Related]

  • 2. Neuroradiological and eye movement correlates in children with intermittent saccade failure: "ocular motor apraxia".
    Shawkat FS, Kingsley D, Kendall B, Russell-Eggitt I, Taylor DS, Harris CM.
    Neuropediatrics; 1995 Dec; 26(6):298-305. PubMed ID: 8719744
    [Abstract] [Full Text] [Related]

  • 3. Type 3 Gaucher's disease in a three-year-old child: saccadic eye movements analysis.
    Accardo A, Bembi B, Pensiero S, Perissutti P.
    J AAPOS; 2005 Oct; 9(5):501-3. PubMed ID: 16213406
    [Abstract] [Full Text] [Related]

  • 4. Intermittent horizontal saccade failure ('ocular motor apraxia') in children.
    Harris CM, Shawkat F, Russell-Eggitt I, Wilson J, Taylor D.
    Br J Ophthalmol; 1996 Feb; 80(2):151-8. PubMed ID: 8814747
    [Abstract] [Full Text] [Related]

  • 5. The role of ERG/VEP and eye movement recordings in children with ocular motor apraxia.
    Shawkat FS, Harris CM, Taylor DS, Kriss A.
    Eye (Lond); 1996 Feb; 10 ( Pt 1)():53-60. PubMed ID: 8763304
    [Abstract] [Full Text] [Related]

  • 6. Audiometric abnormalities in children with Gaucher disease type 3.
    Bamiou DE, Campbell P, Liasis A, Page J, Sirimanna T, Boyd S, Vellodi A, Harris C.
    Neuropediatrics; 2001 Jun; 32(3):136-41. PubMed ID: 11521209
    [Abstract] [Full Text] [Related]

  • 7. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 8. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
    Kaplan P, Andersson HC, Kacena KA, Yee JD.
    Arch Pediatr Adolesc Med; 2006 Jun; 160(6):603-8. PubMed ID: 16754822
    [Abstract] [Full Text] [Related]

  • 9. Abnormal vertical optokinetic nystagmus in infants and children.
    Garbutt S, Harris CM.
    Br J Ophthalmol; 2000 May; 84(5):451-5. PubMed ID: 10781506
    [Abstract] [Full Text] [Related]

  • 10. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 11. Clinical and enzyme studies in Gaucher disease.
    Kaur M, Kabra M, Kher A, Naik G, Bharucha BA, Verma IC.
    Indian Pediatr; 1996 Sep 20; 33(9):735-8. PubMed ID: 9057400
    [Abstract] [Full Text] [Related]

  • 12. [Eye movement abnormalities as a sign for the diagnosis in Niemann-Pick disease type C].
    Lengyel D, Weissert M, Schmid L, Gottlob I.
    Klin Monbl Augenheilkd; 1999 Jan 20; 214(1):50-2. PubMed ID: 10198883
    [Abstract] [Full Text] [Related]

  • 13. Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.
    Machaczka M, Paucar M, Björkvall CK, Smith NJC, Cox TM, Forsgren L, Svenningsson P.
    Blood Cells Mol Dis; 2018 Feb 20; 68():86-92. PubMed ID: 27789132
    [Abstract] [Full Text] [Related]

  • 14. Eye movements in a familial vestibulocerebellar disorder.
    Harris CM, Walker J, Shawkat F, Wilson J, Russell-Eggitt I.
    Neuropediatrics; 1993 Jun 20; 24(3):117-22. PubMed ID: 8355816
    [Abstract] [Full Text] [Related]

  • 15. Coagulation abnormalities in type 1 Gaucher disease in children.
    Deghady A, Marzouk I, El-Shayeb A, Wali Y.
    Pediatr Hematol Oncol; 2006 Jun 20; 23(5):411-7. PubMed ID: 16728361
    [Abstract] [Full Text] [Related]

  • 16. Gaucher disease--Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment.
    Erikson A.
    Acta Paediatr Scand Suppl; 1986 Jun 20; 326():1-42. PubMed ID: 3296644
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic stem cell transplantation or enzyme replacement therapy in Gaucher disease type 3.
    Høj A, Ørngreen MC, Naume MM, Lund AM.
    Mol Genet Metab; 2024 Aug 20; 142(4):108515. PubMed ID: 38909587
    [Abstract] [Full Text] [Related]

  • 18. Saccade testing in the diagnosis and treatment of type 3 Gaucher disease.
    Pensiero S, Accardo A, Pittis MG, Ciana G, Bembi B, Perissutti P.
    Neurology; 2005 Dec 13; 65(11):1837. PubMed ID: 16344538
    [No Abstract] [Full Text] [Related]

  • 19. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 13; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 20. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 13; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.